Google
PRPH Stock Analysis — PROPHASE LABS INC (Healthcare >> Diagnostics & Research)
PRPH FAQ
What is PRPH's ROE?
PROPHASE LABS INC reports a Return on Equity (ROE) of 4,064.70%.
What is PRPH's dividend yield?
PROPHASE LABS INC offers a dividend yield of 0.00%.
What is PRPH's Quality Score?
Our AI rates PRPH's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PRPH?
Our AI Timing Score for PRPH is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PRPH belong to?
PROPHASE LABS INC is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
PRPH AI Analysis Summary
Our AI summary for PRPH: PROPHASE LABS INC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of 4,064.70%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.04
Price
-0.02
(-32.03%)
Day Change
|
|
|---|
PRPH, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROA is relatively low.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.04 |
| PBV / Sector |
-1.30 / -29.69
|
| Earning Per Share | -1.30 |
| PE / Sector |
N/A / 48.18
|
| PEG or PE/Growth / Sector |
N/A / 1.64
|
| Average 1M Daily Value |
4381.012795000000
|
| Average 1W Daily Value |
4051.219540000000
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:21 |
| Symbol | PRPH |
| Name | PROPHASE LABS INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 14.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.77 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 626 RXR Plaz, Uniondale, NY, United States, 11556
Phone: 516 989 0763
Website: https://www.prophaselabs.com
Description: ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
